En højere procentdel af patienterne som fik Visudyne sammenlignet med dem som fik placebo, oplevede bivirkninger (89, 3% versus 82, 5%), associerede bivirkninger (42, 7% versus 18, 4%) og hændelser som førte til seponering (6, 2% versus 0, 9%).
A higher percentage of patients who received Visudyne, compared with those who received placebo, experienced adverse events (89.3% versus 82.5%), associated adverse events (42.7% versus 18.4%) and events leading to discontinuation (6.2% versus 0.9%).